INN name:
|
Altiratinib
|
||||||||||
Lab codes:
|
DCC-2701;
DP-5164
|
||||||||||
Trade name:
|
Not
yet marketed
|
||||||||||
Chemical
name:
|
N-{4-[(2-cyclopropanecarboxamidopyridin-4-yl)oxy]-2,5-difluorophenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
||||||||||
Molecular
formula:
|
C26H21F3N4O4
|
||||||||||
Chemical
Structure:
|
 |
||||||||||
CAS Registry
Number:
|
1345847-93-9
|
||||||||||
Originator:
|
Deciphera
Pharmaceuticals
|
||||||||||
Class:
|
Antineoplastics
|
||||||||||
Mechanism of
Action:
|
Tyrosine
kinase inhibitor
|
||||||||||
WHO ATC code:
|
L01X-E
(Protein kinase inhibitors)
|
||||||||||
EPhMRA code:
|
L1H
(Protein Kinase Inhibitor Antineoplastics)
|
||||||||||
FDA
approval:
|
Not
yet approved
|
||||||||||
Clinical Trials:
|
|||||||||||
Product Patent Expiry:
* Patent expiry based
on application, granted patent expiry may differ.
It is possible to
extend the term of a patent in USA, KR and JP. The extension granted at the
time of writing this post has been included and marked with **. Please leave
a comment below for any update.
|
|||||||||||
Recent activities on the drug:
|
|||||||||||
Wednesday, 26 August 2015
Altiratinib
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment